Feasibility Study of EndoTAG-1, a Tumor Endothelial Targeting Agent, in Combination with Paclitaxel followed by FEC as Induction Therapy in HER2-Negative Breast Cancer

BACKGROUND: EndoTAG-1, a tumor endothelial targeting agent has shown activity in metastatic triple-negative breast cancer (BC) in combination with paclitaxel. METHODS: HER2-negative BC patients candidates for neoadjuvant chemotherapy were scheduled to receive 12 cycles of weekly EndoTAG-1 22mg/m(2)...

Descripción completa

Detalles Bibliográficos
Autores principales: Ignatiadis, Michail, Zardavas, Dimitrios, Lemort, Marc, Wilke, Celine, Vanderbeeken, Marie-Catherine, D’Hondt, Veronique, De Azambuja, Evandro, Gombos, Andrea, Lebrun, Fabienne, Dal Lago, Lissandra, Bustin, Fanny, Maetens, Marion, Ameye, Lieveke, Veys, Isabelle, Michiels, Stefan, Paesmans, Marianne, Larsimont, Denis, Sotiriou, Christos, Nogaret, Jean-Marie, Piccart, Martine, Awada, Ahmad
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2016
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4959730/
https://www.ncbi.nlm.nih.gov/pubmed/27454930
http://dx.doi.org/10.1371/journal.pone.0154009

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4959730/
https://www.ncbi.nlm.nih.gov/pubmed/27454930
http://dx.doi.org/10.1371/journal.pone.0154009

Ejemplares similares